Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RCUS vs NTLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NTLA Captures Overall Composite Edge (50.7 HOLD vs 48.4 HOLD), While RCUS Leads 5–1 on Growth & Valuation Pillars

NTLA Overall Winner 6-Pillar Tally: RCUS 5 – 1 NTLA Matrix Metrics: RCUS 2 – 5 NTLA

As of Nov 16, 2026, Intellia Therapeutics, Inc (NTLA) captures the overall head-to-head institutional edge over Arcus Biosciences, Inc. (RCUS) on higher Unified Composite conviction (50.7/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–2 (led by R&D & Supply-Chain Moat), while RCUS wins 5–1 across the 6-pillar growth and valuation breakdown. RCUS trades at $16.97 (N/M Forward P/E, -475.0% operating margin) versus NTLA at $10.00 (N/M Forward P/E, -826.0% operating margin).

  • Growth vs. Quality Trade-Off: NTLA earns the overall head-to-head edge with a stronger Unified Composite Score (50.7/100 HOLD vs. RCUS 48.4/100 HOLD) and 2.30β · 87% Vol risk profile, whereas RCUS leads top-line expansion (-65.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RCUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RCUS vs NTLA
RCUS NYSE
Arcus Biosciences, Inc.
Pharmaceutical Preparations
$16.97
-2.64% 1D
Market Cap $2.6B
TTM Revenue $100M
Forward P/E N/M
Beta / 30D Vol 1.56β · 90% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 48.0 Fund 59.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 33
RSI-14: 33.3 · SMA20: $18.62 · SMA50: $22.36
NTLA NASDAQ Head-to-Head Winner
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86

6-Pillar Scorecard Institutional Category Breakdown (RCUS 5 – 1 NTLA)

Columns: Metric · RCUS · NTLA
1. Valuation Multiples RCUS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 25.2x 29.1x
2. Growth & Scale RCUS
Revenue Growth (YoY) -65.4% -48.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $100M $53M
Market Cap $2.6B $1.5B
3. Profitability & Quality RCUS
Gross Margin N/A N/A
Operating Margin -475.0% -826.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -114.1% -62.6%
4. Balance Sheet & Cash Flow RCUS
Cash Generation (TTM) -$466M -$358M
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $74M Net Debt (0.38x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCUS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 43.1% (1st %ile) 101.3% (78th %ile)
Put/Call OI Skew 0.08x (Call-Skewed) 0.42x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RCUS (2) vs NTLA (5)
Institutional Metric RCUS NTLA Criterion Row Edge
Market Capitalization
Scale
$2.6B $1.5B Larger Scale RCUS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-65.4% -48.0% Higher Growth NTLA
Operating Margin (TTM)
Profitability
-475.0% -826.0% Higher Margin RCUS
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-114.1% -62.6% Higher ROE NTLA
52-Week Range Position
Momentum
1% ($17–$32) 20% ($8–$18) Stronger Trend NTLA
Beta / 30D Volatility
Risk Regime
1.56β · 90% Vol 2.30β · 87% Vol Lower Realized Risk NTLA
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 50.7 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$100M $53M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 25.2x EV/Rev N/M PEG · 29.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$466M ($35M Net Cash) -$358M ($74M Net Debt (0.38x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NTLA +10.85 pp
RCUS: -23.28% · NTLA: -12.43%
3M Horizon NTLA +28.7 pp
RCUS: -42.49% · NTLA: -13.79%
6M Horizon NTLA +6.28 pp
RCUS: -27.48% · NTLA: -21.2%
1Y Horizon NTLA +29.59 pp
RCUS: -14.25% · NTLA: +15.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RCUS Revenue NTLA Revenue RCUS Op. Margin NTLA Op. Margin Margin Leader
FY2018 $10M $30M -656.8% -298.6% NTLA
FY2019 $10M $40M -591.4% -246.8% NTLA
FY2020 $80M $60M -159.0% -235.5% RCUS
FY2021 $380M $30M 14.1% -810.4% RCUS
FY2022 $40M $50M -736.8% -879.0% RCUS
FY2023 $40M $40M -918.9% -1420.5% RCUS
FY2024 $50M $60M -647.1% -923.1% RCUS
FY2025 $30M $70M -1169.7% -651.7% NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RCUS BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 43.1%
IV Percentile 1st %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RCUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RCUS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.6B market capitalization and -475.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ RCUS vs NTLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Intellia Therapeutics, Inc (NTLA) captures the overall head-to-head institutional edge over Arcus Biosciences, Inc. (RCUS) on higher Unified Composite conviction (50.7/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–2 (led by R&D & Supply-Chain Moat), while RCUS wins 5–1 across the 6-pillar growth and valuation breakdown. RCUS trades at $16.97 (N/M Forward P/E, -475.0% operating margin) versus NTLA at $10.00 (N/M Forward P/E, -826.0% operating margin). Growth vs. Quality Trade-Off: NTLA earns the overall head-to-head edge with a stronger Unified Composite Score (50.7/100 HOLD vs. RCUS 48.4/100 HOLD) and 2.30β · 87% Vol risk profile, whereas RCUS leads top-line expansion (-65.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RCUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCUS leads the Growth & Scale pillar: RCUS posts -65.4% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (N/A gross margin, -475.0% operating margin), compared with NTLA at -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RCUS cumulative revenue shifted +200.0% while NTLA shifted +133.3%. In operating R&D and SG&A reinvestment, RCUS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NTLA.

RCUS screens cheaper on headline valuation multiples. RCUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 25.2x EV/Revenue (unreported FCF margin), whereas NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RCUS (-114.1% ROE) versus NTLA (-62.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RCUS carries 43.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 90% Vol realized risk). By comparison, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.